The challenges of hepatitis C diagnosis and the potential role of Stimmunology™ to address them

Antiviral Therapy

Volumn 17, Issue 7 PARTB, 2012, Pages 1415-1422

  Jehuda Cohen, Tamar ^a,b   Unal, Serhat ^c  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b SMART Biotech Ltd   (Israel)

^c HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ANTIBODY; VIRUS ANTIGEN;

ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY PRODUCTION; B LYMPHOCYTE; DIAGNOSTIC EQUIPMENT; FALSE POSITIVE RESULT; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION RATE; LONG SERONEGATIVE WINDOW PERIOD; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; VIRUS DETECTION;

FALSE POSITIVE REACTIONS; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HEPATITIS C ANTIGENS; HUMANS; LYMPHOCYTES; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 84872000450     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2472     Document Type: Review

References (50)

1. Centers for Disease Control and Prevention. Sexually transmitted diseases; treatment guidelines 2006, hepatitis C. (Updated 12 April 2007. Accessed 5 September 2012.) Available from http://www.cdc.gov/std/treatment/ 2006/hepatitis-c.htm
2. Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 2005; 436:946-952.
3. Busch MP, Shafer KA. Acute-phase hepatitis C virus infection: implications for research, diagnosis, and treatment. Clin Infect Dis 2005; 40:959-961.
4. Ward JW, Averhoff FM, Koh HK. World Hepatitis Day: a new era for hepatitis control. Lancet 2011; 378:552-553.
5. CDC Viral Hepatitis - HCV Symposium, December 2011. (Accessed 13 September 2012.) Available from http://www.cdc.gov/hepatitis/Resources/MtgsConf/ HCVSymposium2011.htm
6. Burki T. World Hepatitis Day to tackle viral hepatitis. Lancet Infect Dis 2011; 11:589-590.
7. Stramer SL, Glynn SA, Kleinman SH, et al. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med 2004; 351:760-768.
8. Soldan K, Davison K, Dow B. Estimates of the frequency of HBV, HCV, and HIV infectious donations entering the blood supply in the United Kingdom, 1996 to 2003. Euro Surveill 2005; 10:17-19.
9. Kim AY, Schulze zur Wiesch J, Kuntzen T, et al. Impaired hepatitis C virus-specific T-cell responses and recurrent hepatitis C virus in HIV coinfection. PLoS Med 2006; 3:e492.
10. Zhang L, Chen Z, Cao Y, et al. Molecular characterization of human immunodeficiency virus type 1 and hepatitis C virus in paid blood donors and injection drug users in China. J Virol 2004; 78:13591-13599.
11. Plamondon M, Labbé AC, Frost E, et al. Hepatitis C virus infection in Guinea-Bissau: a sexually transmitted genotype 2 with parenteral amplification? PLoS ONE 2007; 2:e372.
12. CDC. Sexually transmitted diseases treatment guidelines, 2010. (Updated 13 August 2012. Accessed 5 September 2012.) Available from http://www.cdc.gov/ std/treatment/2010/
13. Hézode C. Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice. Liver Int 2012; 32 Suppl 1:32-38.
14. Two protease inhibitors for HCV. Victrelis, Incivek. Pharmacy and Therapeutics 2011; 36:320-331.
15. Adiwijaya BS, Kieffer TL, Henshaw J, et al. A viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis C infection. PLoS Comput Biol 2012; 8:e1002339.
16. Vermehren J, Sarrazin C. New hepatitis C therapies in clinical development. Eur J Med Res 2011; 16:303-314.
17. Horn T. Telaprevir greatly boosts early hep C treatment responses in HIV-coinfected patients. 18th Conference on Retroviruses and Opportunistic Infections (CROI). 27 February - 2 March 2011, Boston, MA, USA.
18. Dominguez S, Ghosn J, Valantin MA, et al. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients. AIDS 2006; 20:1157-1161.
19. Delwaide J, Bourgeois N, Gérard C, et al. Treatment of acute hepatitis C with interferon alpha-2b: early initiation of treatment is the most effective predictive factor of sustained viral response. Aliment Pharmacol Ther 2004; 20:15-22.
20. CDC. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep 1998; 47 RR-19:1-39.
21. CDC HIV/AIDS Science Facts. CDC releases revised HIV testing recommendations in healthcare settings. (Updated September 2006. Accessed 5 September 2012.) Available from http://www.cdc.gov/hiv/topics/testing/resources/ factsheets/pdf/healthcare.pdf
22. Sroczynski G, Esteban E, Conrads-Frank A, et al. Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection. Eur J Public Health 2009; 19:245-253.
23. WHO. Hepatitis C virus. (Accessed 6 September 2007.) Available from http://www.who.int/vaccine-research/diseases/viral-cancers/en/index2.html
24. Alter H, Jett B, Polito A. Analysis of the role of hepatitis C virus in transfusion associated hepatitis. In Hollinger FB, Margolis H (Editors). Viral hepatitis and liver disease. Baltimore: Williams & Williams 1991; pp. 396-402.
25. Delwart EL, Kalmin ND, Jones TS, et al. First report of human immunodeficiency virus transmission via an RNA-screened blood donation. Vox Sang 2004; 86:171-177.
26. Roth WK, Weber M, Buhr S, et al. Yield of HCV and HIV-1 NAT after screening of 3.6 million blood donations in central Europe. Transfusion 2002; 42:862-868.
27. Kretzschmar E, Chudy M, Nübling CM, et al. First case of hepatitis C virus transmission by a red blood cell concentrate after introduction of nucleic acid amplification technique screening in Germany: a comparative study with various assays. Vox Sang 2007; 92:297-301.
28. Kolk DP, Dockter J, Linnen J, et al. Significant closure of the human immunodeficiency virus type 1 and hepatitis C virus preseroconversion detection windows with a transcription-mediated-amplification-driven assay. J Clin Microbiol 2002; 40:1761-1766.
29. Icardi G, Ansaldi F, Bruzzone BM, et al. Novel approach to reduce the hepatitis C virus (HCV) window period: clinical evaluation of a new enzyme-linked immunosorbent assay for HCV core antigen. J Clin Microbiol 2001; 39:3110-3114.
30. Medhi S, Potukuchi SK, Polipalli SK, et al. Diagnostic utility of hepatitis C virus core antigen in hemodialysis patients. Clin Biochem 2008; 41:447-452.
31. Netski DM, Mosbruger T, Depla E, et al. Humoral immune response in acute hepatitis C virus infection. Clin Infect Dis 2005; 41:667-675.
32. Cao J, Chen Q, Zhang H, et al. Novel evolved immunoglobulin (Ig)-binding molecules enhance the detection of IgM against hepatitis C virus. PLoS ONE 2011; 6:e18477.
33. CDC. Hemodialysis and Viral Hepatitis. Hepatitis C Testing. Centers for Disease Control and Prevention. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep 2001; 50 RR-5:1-63.
34. Contreras AM, Tornero-Romo CM, Toribio JG, et al. Very low hepatitis C antibody levels predict false-positive results and avoid supplemental testing. Transfusion 2008; 48:2540-2548.
35. Watterson JM, Stallcup P, Escamilla D, Chernay P, Reyes A, Trevino SC. Evaluation of the Ortho-Clinical Diagnostics Vitros ECi Anti-HCV test: comparison with three other methods. J Clin Lab Anal 2007; 21:162-166.
36. Kita M, Deguchi M, Kagita M, et al. Clinical utility and characteristics of nine anti-HCV antibody screening reagents used in Japan. Clin Lab 2009; 55:9-22.
37. Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003; 125:80-88.
38. Santantonio T, Fasano M, Sinisi E, et al. Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J Hepatol 2005; 42:329-333.
39. Cox AL, Netski DM, Mosbruger T, et al. Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin Infect Dis 2005; 40:951-958.
40. Larghi A, Zuin M, Crosignani A, et al. Outcome of an outbreak of acute hepatitis C among healthy volunteers participating in pharmacokinetics studies. Hepatology 2002; 36:993-1000.
41. Jauncey M, Micallef J, Gilmour S, et al. Clearance of hepatitis C virus after newly acquired infection in injection drug users. J Infect Dis 2004; 190:1270-1274.
42. Takaki A, Wiese M, Maertens G, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 2000; 6:578-582.
43. Keating S, Coughlan S, Connell J, Sweeney B, Keenan E. Hepatitis C viral clearance in an intravenous drug-using cohort in the Dublin area. Ir J Med Sci 2005; 174:37-41.
44. Heyman B. Regulation of antibody responses via antibodies, complement and Fc receptors. Annu Rev Immunol 2000; 18:709-737.
45. Ciuffreda D, Kim AY. Update on hepatitis C virus-specific immunity. Curr Opin HIV AIDS 2011; 6:559-565.
46. Jehuda-Cohen T. The HIV seronegative window period: diagnostic challenges and solutions. In Tang Y-W (Editor). Recent translational research in HIV/AIDS. Rijeka, Croatia: InTech 2011; pp. 179-202.
47. Novikov I, Jehuda-Cohen T. HIV Type 1 infection among Ethiopian immigrants to Israel: enhanced in vitro antibody stimulation for estimating the length of the window period. AIDS Res Hum Retroviruses 2009; 25:165-174.
48. Mumo J, Vansover A, Jehuda-Cohen T. Detecting seronegative-early HIV infections among adult versus student Kenyan blood donors, by using Stimmunology. Exp Biol Med (Maywood) 2009; 234:931-939.
49. Jehuda-Cohen T, Gorodin S. Overcoming, in-vitro, the specific immune suppression during the window period of HCV infection enables the detection of currently missed infected individuals. 13th International Symposium on Viral Hepatitis and Liver Disease. 20-24 March 2009, Washington DC, USA.
50. Durmaz N, Sener B, Gumusluoglu B, et al. [Use of Smartube in determination of antibodies by ELISA method for the diagnosis of HIV and HCV infections]. Turk HIV/AIDS Dergisi 2006; 9:112-116. Turkish.